Examkin

Question

Difficulty: MediumDiagnostic Workup and Test Sequencing

A 45-year-old man with a history of recurrent nephrolithiasis presents with severe, medically refractory gastroesophageal reflux and chronic diarrhea. Recent esophagogastroduodenoscopy revealed prominent gastric folds and multiple ulcerations in the distal duodenum. The clinical picture is highly suspicious for Zollinger-Ellison syndrome, potentially in the setting of Multiple Endocrine Neoplasia type 1. Arrange the following diagnostic steps in the most appropriate chronological sequence to establish the biochemical diagnosis and definitively localize the responsible tumor.

  1. 1Measurement of fasting serum gastrin level and gastric pH
  2. 2Secretin stimulation test
  3. 3Somatostatin receptor positron emission tomography (PET/CT)
  4. 4Endoscopic ultrasonography (EUS)

Answer

The correct sequence begins with initial biochemical screening (fasting serum gastrin and pH), followed by a confirmatory functional test (secretin stimulation), then non-invasive tumor localization (Somatostatin receptor PET/CT), and finally invasive localization if needed (Endoscopic ultrasonography).
The diagnostic workup for Zollinger-Ellison syndrome follows a strict sequence: initial biochemical screening, confirmatory functional testing, non-invasive imaging, and finally invasive imaging. Fasting serum gastrin with gastric pH is the most appropriate first step to identify inappropriate hypergastrinemia. Because many patients have equivocal gastrin levels, a secretin stimulation test is required to confirm autonomous gastrin secretion. Once biochemically confirmed, Somatostatin receptor PET/CT is the initial imaging test of choice due to its high sensitivity for finding primary tumors and metastases. If this fails to identify the lesion, Endoscopic ultrasonography (EUS) is indicated to carefully evaluate the gastrinoma triangle.

Step-by-Step Solution

1
Establish the initial biochemical presence of hypergastrinemia.
Measurement of fasting serum gastrin and gastric pH is obtained.
This screening test determines if there is an inappropriate elevation of gastrin in the setting of high acid production, differentiating it from secondary hypergastrinemia due to achlorhydria.
2
Confirm the diagnosis of a gastrinoma.
A secretin stimulation test is performed.
Secretin paradoxically stimulates the release of gastrin from gastrinoma cells. This differentiates Zollinger-Ellison syndrome from other causes of hypergastrinemia, especially when initial screening levels are equivocal.
3
Perform initial non-invasive tumor localization.
Somatostatin receptor PET/CT (e.g., Gallium-68 DOTATATE) is ordered.
Gastrinomas overexpress somatostatin receptors. This imaging modality is the most sensitive non-invasive method for localizing the primary tumor and detecting hepatic or bone metastases.
4
Proceed with invasive localization if the tumor is not identified.
Endoscopic ultrasonography (EUS) is utilized.
EUS provides high-resolution imaging of the pancreas and duodenum (the gastrinoma triangle) and allows for fine-needle aspiration if small, occult tumors are not seen on systemic imaging.

Key Concept

The diagnostic algorithm for Zollinger-Ellison syndrome requires confirming hypergastrinemia, functionally proving autonomous gastrin secretion, and subsequently progressing from non-invasive to invasive tumor localization.
Estimated Time:1m 30s
Rate this question

Topics

Diagnostic Workup and Test Sequencing

More questions from this topic